Molecule
Fosaprepitant is a substance P/neurokinin-1 receptor antagonist. It is available as powder for injection and injection for intravenous use. MedsAcross supplies Fosaprepitant for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
EMEND ® for injection, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).
Source: US FDA prescribing information
Fosaprepitant is a prodrug of aprepitant and accordingly, its antiemetic effects are attributable to aprepitant. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK 1 ) receptors. Aprepitant has little or no affinity for serotonin (5-HT 3 ), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CINV). Aprepitant has been shown in animal models to inhibit emesis induced by cytotoxic chemotherapeutic agents, such as cisplatin, via central actions. Animal and human Positron Emission Tomography (PET) studies with aprepitant have shown that it crosses the blood brain barrier and occupies brain NK 1 receptors.
Source: US FDA prescribing information
Recommended Adult Dosage. EMEND for injection 150 mg on Day 1 as an intravenous infusion over 20 to 30 minutes. Complete the infusion approximately 30 minutes prior to chemotherapy. Recommended Dosage for Pediatric Patients (6 months to 17 years) Weighing at Least 6 kg. See Full Prescribing Information for pediatric dosage regimens by age. For single dose chemotherapy regimens: single dose of EMEND for injection on Day 1. For single- or multi-day chemotherapy regimens: 3-day EMEND regimen of EMEND for injection on Days 1, 2, and 3. EMEND capsules or EMEND for oral suspension may be used as an alternative on Days 2 and 3. Administer EMEND for injection through a central venous catheter as an intravenous infusion over 30 minutes (12 years to 17 years) or 60 minutes (6 months to less than 12 years). Concomitant Antiemetics See Full Prescribing Information for additional information.
Source: US FDA prescribing information
EMEND is contraindicated in patients: who are hypersensitive to any component of the product. Hypersensitivity reactions including anaphylactic reactions, flushing, erythema, and dyspnea have been reported. taking pimozide. Inhibition of CYP3A4 by aprepitant, the active moiety, could result in elevated plasma concentrations of this drug, which is a CYP3A4 substrate, potentially causing serious or life-threatening reactions, such as QT prolongation, a known adverse reaction of pimozide. Known hypersensitivity to any component of this drug. Concurrent use with pimozide.
Source: US FDA prescribing information
CYP3A4 Interactions: Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4, see Full Prescribing Information for recommendations regarding contraindications, risk of adverse reactions, and dosage adjustment of EMEND and concomitant drugs. Hypersensitivity Reactions (including anaphylaxis and anaphylactic shock): May occur during or soon after infusion. If symptoms occur, discontinue the drug. Do not reinitiate EMEND if symptoms occur with previous use. Infusion Site Reactions (including thrombophlebitis, necrosis, and vasculitis): Majority of reactions reported in patients receiving vesicant chemotherapy. Avoid infusion into small veins. Discontinue infusion and administer treatment if a severe reaction develops.
Source: US FDA prescribing information
The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity Reactions Infusion Site Reactions Most common adverse reactions in adults (≥2%) are: fatigue, diarrhea, neutropenia, asthenia, anemia, peripheral neuropathy, leukopenia, dyspepsia, urinary tract infection, pain in extremity. Adverse reactions in pediatrics are similar to adults.
Source: US FDA prescribing information
See Full Prescribing Information for a list of clinically significant drug interactions. Effect of Fosaprepitant/Aprepitant on the Pharmacokinetics of Other Drugs When administered intravenously, fosaprepitant, a prodrug of aprepitant, is converted to aprepitant within 30 minutes. Therefore, drug interactions following administration of EMEND for injection are likely to occur with drugs that interact with oral aprepitant. Fosaprepitant, given as a single 150-mg dose, is a weak inhibitor of CYP3A4, and the weak inhibition of CYP3A4 continues for 2 days after single dose administration. Single dose fosaprepitant does not induce CYP3A4. Aprepitant is a substrate, an inhibitor, and an inducer of CYP3A4. Aprepitant is also an inducer of CYP2C9. Some substrates of CYP3A4 are contraindicated with EMEND.
Source: US FDA prescribing information
Emend for injection vials must be refrigerated, store at 2°C-8°C (36°F-46°F). The reconstituted final drug solution is stable for 24 hours at ambient room temperature [at or below 25°C (77°F)].
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
5 presentations of Fosaprepitant, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Fosaprepitant 150 mg/5 mL powder for injectionIntravenous Cold chainGeneric name | — | US FDA | Available on request |
| Focinvez 150 mg/50 mL injectionIntravenous Cold chain | Steriscience SpecialtiesIndia | US FDA | Available on request |
| Fosaprepitant 150 mg powder for injectionIntravenous Cold chainGeneric name | — | US FDA | Available on request |
| Emend 150 mg/5 mL powder for injectionIntravenous Cold chain | Merck Sharp & Dohme | US FDA | Available on request |
| Navitrux 150 mg/5 mL powder for injectionIntravenous Cold chain | Avyxa Pharma | US FDA | Available on request |
3 brand names across 1 markets.
Indian manufacturers are highlighted.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 5 presentations of Fosaprepitant and sources them for licensed hospitals, importers and physicians against valid import documents. Indian manufacturers include Steriscience Specialties.
The catalogue lists 3 brand names for Fosaprepitant, including Emend, Focinvez, Navitrux.
Yes. The US FDA first approved Fosaprepitant on 25 January 2008, according to Drugs@FDA.
Yes. Fosaprepitant has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Fosaprepitant must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Fosaprepitant is classified under ATC code A04AD12 (Fosaprepitant).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.